tiprankstipranks
Immune Therapeutics (IMUN)
OTHER OTC:IMUN
US Market

Immune Therapeutics (IMUN) Stock Price & Analysis

9 Followers

IMUN Stock Chart & Stats

Day’s Range$0.09 - $0.09
52-Week Range― - ―
Previous Close$0.1
Volume12.00
Average Volume (3M)N/A
Market Cap
$6.69M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
May 15, 2018
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

IMUN FAQ

What was Immune Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Immune Therapeutics’s market cap?
Currently, no data Available
When is Immune Therapeutics’s upcoming earnings report date?
Immune Therapeutics’s upcoming earnings report date is May 15, 2018 which is 2145 days ago.
    How were Immune Therapeutics’s earnings last quarter?
    Currently, no data Available
    Is Immune Therapeutics overvalued?
    According to Wall Street analysts Immune Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
      Does Immune Therapeutics pay dividends?
      Immune Therapeutics does not currently pay dividends.
      What is Immune Therapeutics’s EPS estimate?
      Immune Therapeutics’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does Immune Therapeutics have?
      Currently, no data Available
      What happened to Immune Therapeutics’s price movement after its last earnings report?
      Currently, no data Available
      Which hedge fund is a major shareholder of Immune Therapeutics?
      Currently, no hedge funds are holding shares in IMUN
      ---

      Immune Therapeutics Stock Smart Score

      N/A
      Not Ranked
      1
      2
      3
      4
      5
      6
      7
      8
      9
      10

      Technicals

      SMA
      Negative
      20 days / 200 days
      Momentum
      -93.22%
      12-Months-Change

      Fundamentals

      Return on Equity
      Trailing 12-Months
      Asset Growth
      179.40%
      Trailing 12-Months

      Company Description

      Immune Therapeutics

      Immune Therapeutics, Inc. is a biopharmaceutical company focuses on the commercialization of affordable non-toxic immunotherapies focused on the activation and rebalancing of the body's immune system. It specializes in the treatment of cancers, HIV, autoimmune diseases, inflammatory conditions, and other opportunistic infections for chronic often life-threatening diseases through the mobilization of the body's immune system in emerging nations using existing clinical data. The company was founded by Noreen Griffin on December 2, 1993 and is headquartered in Orlando, FL.
      ---
      Similar Stocks
      Company
      Price & Change
      Follow
      Atreca
      Abeona Therapeutics
      Advaxis
      Omeros
      Popular Stocks
      ---
      What's Included in PREMIUM?
      Make informed decisions based on Top Analysts' activity
      Know what industry insiders are buying
      Get actionable alerts from top Wall Street Analysts
      Find out before anyone else which stock is going to shoot up
      Get powerful stock screeners & detailed portfolio analysis